Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, with the fireside chat available on demand beginning June 15 at 7:00 a.m. EDT. This engagement provides Helus Pharma with a platform to discuss its pipeline and the potential of its proprietary NSAs to transform the treatment landscape for mental health disorders.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing synthetic molecules designed to activate serotonin pathways, which are believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs address significant unmet needs, as millions of people worldwide suffer from depression and anxiety with limited effective treatment options.
The company's participation in the H.C. Wainwright conference is significant because it allows Helus Pharma to present its clinical data and development strategy to the investment community. The on-demand fireside chat format ensures broad accessibility, enabling investors and analysts to gain insights into the company's progress and future milestones. As Helus Pharma advances its pipeline, the outcomes of its clinical trials could have substantial implications for the mental health field, potentially offering new therapeutic options that provide durable improvements.
For more details, the full press release is available at https://ibn.fm/KsnJW. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, and continues to expand its research portfolio of investigational NSAs. The company's commitment to innovation positions it as a key player in the evolving mental health treatment landscape.
